[1]范 丽,张 婷.拉米夫定、阿德福韦酯、恩替卡韦治疗失代偿期乙型肝炎肝硬化临床研究[J].陕西医学杂志,2019,(7):939-941.
　FAN Li,ZHANG Ting..Comparison of the efficacy of LAM，ADV and ETV in the treatment of decompensated hepatitis B cirrhosis[J].,2019,(7):939-941.
点击复制

拉米夫定、阿德福韦酯、恩替卡韦治疗失代偿期乙型肝炎肝硬化临床研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2019年7期
页码:
939-941
栏目:
药物与临床
出版日期:
2019-07-05

文章信息/Info

Title:
Comparison of the efficacy of LAM，ADV and ETV in the treatment of decompensated hepatitis B cirrhosis
文章编号:
DOI:10.3969/j.issn.1000-7377.2019.07.036
作者:
范 丽; 张 婷
西安医学院第二附属医院消化内科（西安 710038）
Author(s):
FAN Li;  ZHANG Ting.
Department of Gastroenterology,Second Affiliated Hospital of Xi’an Medical College(Xi’an 710038)
关键词:
失代偿期乙型肝炎肝硬化; 拉米夫定; 阿德福韦酯; 恩替卡韦;  慢性乙型肝炎病毒; 联合治疗
Keywords:
Key words Decompensated hepatitis B cirrhosis; Lamivudine; Adefovir dipivoxil; Entecavir; Chronichepatitis bvirus; Combination therapy
分类号:
R512.62
文献标志码:
A
摘要:
摘 要 目的：对拉米夫定（LAM）、阿德福韦酯（ADV）、恩替卡韦（ETV）在失代偿期乙型肝炎肝硬化治疗中效果进行评价。方法：选取收治的150例失代偿期乙型肝炎肝硬化患者，按非随机非劣效性分为A组（n75）、B组（n75），A组接受LAM联合ADV治疗；B组接受ETV治疗；比较两组治疗疗效。结果:随访12个月，A组生存率97.33%，B组生存率97.33%，两组比较，差异无统计学意义（P＞0.05）；两组治疗后肝功能、eGFR、Child-Pugh评分较治疗前改善，两组比较差异有统计学意义（P＜0.05）；两组治疗后各指标及并发症发生率比较，差异无统计学意义（P＞0.05）。结论：对失代偿期乙型肝炎肝硬化患者分别经拉米夫定联合阿德福韦酯、恩替卡韦治疗，均取得显著近期效果，安全性相似。
Abstract:
Abstract Objective:To evaluate the therapeutic effects of lamivudine (LAM)，adefovir dipivoxil (ADV) and entecavir (ETV) in decompensated hepatitis B cirrhosis. Methods:150 patients with decompensated hepatitis B cirrhosis admitted to our hospital from January 2015 to December 2017 were divided into group A (n75) and group B according to non-random non-inferiority.n75)，group A received LAM combined with ADV treatment; group B received ETV treatment; comparing the treatment of the two groups. Results:After 12 months of follow-up，the survival rate of group A was 97.33%，and the survival rate of group B was 97.33%. There was no difference (P＞0.05). The liver function，eGFR and Child-Pugh scores of the two groups were improved after treatment. Significance (P＜0.05); there was no difference in the incidence of each index and complication between the two groups (P＞0.05). Conclusions: In patients with decompensated hepatitis B cirrhosis，lamivudine combined with adefovir dipivoxil and entecavir have achieved significant short-term results with similar safety.

参考文献/References:

[1] 梁志军,李瑞娟,王素娜. 乙肝肝硬化对外周血T细胞亚群、免疫球蛋白及补体水平的影响[J]. 陕西医学杂志,2017,46(12):1655-1656. [2] 陈邦涛，冯旭娇，宋少娟，等.恩替卡韦与拉米夫定联合阿德福韦酯治疗乙型肝炎肝硬化失代偿期患者48周疗效Meta分析[J].实用肝脏病杂，2016，19（3）：305-309. [3] 魏兆勇.拉米夫定联合阿德福韦酯治疗失代偿期乙型肝炎肝硬化临床观察[J].中华医院感染学杂志,2014,24(2):361-363. [4] 中华医学会肝病学分会.慢性乙型肝炎防治指南(2015年版)[J].中华实验和临床感染病杂志：电子版,2015,19(5):1-18. [5] 中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].中华肝脏病杂志,2011,20(11):929-946. [6] 姜宏伟,王哲培.拉米夫定联合阿德福韦酯对失代偿期乙型肝炎肝硬化的临床疗效观察[J].中华医院感染学杂志,2013,23(4):902-903. [7] 蔡 敏,周 慧,刘 娜,等.拉米夫定联合阿德福韦酯对比恩替卡韦单药治疗失代偿期乙型肝炎肝硬化疗效与安全性的Meta分析[J].中国药房,2016,27(27):3814-3817. [8] 张则甫. 柔木丹颗粒联合阿德福韦酯治疗乙肝肝硬化代偿期的临床研究[D].陕西中医学院,2009. [9] 左琳琳,周华娟,方红菊.恩替卡韦治疗46例失代偿期乙型肝炎肝硬化患者临床效果观察[J].实用肝脏病杂志,2016,19(2):217-218. [10] 任维鑫,焦 健,柳 梅.恩替卡韦治疗失代偿期乙型肝炎肝硬化48周疗效观察[J].中国煤炭工业医学杂志,2014,17(2):176-178.

更新日期/Last Update: 2019-07-12